HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

STAT+: No Surprises Act arbitration rule could worsen flood of provider disputes

The arbitration process has protected patients but generated financial windfalls for some clinicians.

By STAT News · Jun 1, 2026 · via STAT News
STAT+: No Surprises Act arbitration rule could worsen flood of provider disputes

Image: STAT News

This is an aggregated industry headline. Read the full story at STAT News →

Tags
theweekformat:headlineheadlineSTAT News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
ASCO: Sac-TMT's massive phase 3 program has a jarring gap. Does Merck plan to close it?
The WeekFiercePharma ↗
ASCO: Sac-TMT's massive phase 3 program has a jarring gap. Does Merck plan to close it?
Merck & Co.'s extensive clinical development scheme for its TROP2 antibody-drug conjugate sac-TMT already …
Jun 1, 2026
Lilly pens $1.2B deal for Hanmi's GLP-2 drug being aimed at short bowel syndrome
The WeekFierceBiotech ↗
Lilly pens $1.2B deal for Hanmi's GLP-2 drug being aimed at short bowel syndrome
Eli Lilly has expanded its glucagon-like peptide portfolio in an intriguing direction by licensing a phase 2-s…
Jun 1, 2026
Revolution Medicines Preps Daraxonrasib FDA Filing, Starts Early Shipments
The WeekBriefing
Revolution Medicines Preps Daraxonrasib FDA Filing, Starts Early Shipments
CEO Mark Goldsmith says the company will soon seek approval for its pancreatic cancer drug daraxonrasib and ha…
Jun 1, 2026